Amicus Therapeutics Discloses Strong Preliminary 2025 Financials Amidst BioMarin Acquisition
Summary
Amicus Therapeutics released preliminary unaudited financial results for 2025, reporting approximately $634 million in total net product revenues and $294 million in cash, cash equivalents, and marketable securities, in connection with its pending acquisition by BioMarin Pharmaceutical Inc.
Key Events
-
Preliminary 2025 Financials Released
Amicus Therapeutics estimates total net product revenues of approximately $634 million for the year ended December 31, 2025.
-
Product Revenue Breakdown
This includes $522 million from Galafold® and $112 million from Pombiliti® + Opfolda®.
-
Strong Cash Position Reported
The company reported an estimated $294 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
-
Context of Pending Acquisition
These preliminary figures were provided to BioMarin Pharmaceutical Inc. in connection with its proposed acquisition of Amicus, which was announced on January 21, 2026.
Analysis
This DEFA14A filing, incorporating an 8-K, provides the first preliminary look at Amicus Therapeutics' full-year 2025 financial performance, which is crucial context for its pending acquisition by BioMarin Pharmaceutical Inc. The reported $634 million in total net product revenues and a strong cash position of $294 million as of year-end 2025 suggest robust operational performance leading into the merger. These figures, though unaudited, offer investors valuable insight into the company's financial health and support the valuation of the $14.50 per share acquisition offer. The disclosure helps shareholders assess the underlying value of Amicus as they consider the proposed transaction.
At the time of this filing, FOLD was trading at $14.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $5.51 to $14.38. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.